Company intelligence / Profile preview
Ocular Therapeutix
Bedford, Massachusetts, USAocutx.com ↗
- Ownership
- Public · OCUL
- Employees
- ~225
- Development stage
- Phase 3
01
Overview
Ocular Therapeutix has an FDA-approved product DEXTENZA® for post-surgical ocular pain/inflammation and allergic conjunctivitis. Its lead pipeline candidate AXPAXLI™ (OTX-TKI) is in Phase 3 trials for wet AMD with topline data expected Q4 2025. Other candidates are in various stages of clinical development targeting major ophthalmic diseases.
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- sustained-release drug delivery systems (hydrogel-based)small molecules (e.g., axitinib)corticosteroidsprostaglandin analogs
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Regeneron Pharmaceuticals – collaboration on extended-release anti–VEGF therapies such as aflibercept formulations
04
Financials
- Market cap
- $2.5B
- Total revenue
- $13.5M
- Enterprise value
- $2B
Beyond the preview
Go deeper on Ocular Therapeutix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocular Therapeutix.